Survodutide: A Dual GLP-1/Glucagon Receptor Agonist
A patient on a stable GLP-1 regimen for eighteen months hits a weight-loss plateau and a liver panel that still shows elevated ALT despite steady adherence. That scenario is exactly the gap survodutide (BI 456906) was designed to test: whether adding glucagon receptor agonism to GLP-1 receptor agonism produces a bigger effect on liver fat than GLP-1 stimulation alone, without giving up the weight-loss benefit patients and researchers expect from this drug class.
Survodutide is a 29-amino-acid acylated peptide developed by Boehringer Ingelheim, built on a C18 fatty diacid moiety that drives greater than 99% binding to human serum albumin. That albumin binding extends the plasma half-life to approximately six days, supporting once-weekly subcutaneous dosing, similar in principle to semaglutide (Ozempic/Wegovy) but built on a dual-receptor pharmacophore rather than a single-receptor one.
Unlike tirzepatide (Mounjaro/Zepbound), which pairs GIP and GLP-1 receptor agonism, survodutide pairs glucagon receptor (GCGR) agonism with GLP-1 receptor (GLP-1R) agonism. The rationale, detailed further in coverage of GLP-1 receptor mechanism of action and tolerability, is that glucagon receptor stimulation independently increases hepatic fatty-acid oxidation and resting energy expenditure, mechanisms distinct from the appetite suppression and delayed gastric emptying that GLP-1 receptor agonism provides on its own. Survodutide remains an investigational compound; it is not FDA-approved and carries no indication for weight management or liver disease as of this writing.
Receptor Pharmacology: Why Adding Glucagon Changes the Profile
Preclinical characterization published in the discovery paper for BI 456906 (PMC9679702) reports EC50 values of approximately 20 pM at the GLP-1 receptor and 108 pM at the glucagon receptor in cAMP-signaling assays, compared with 5 pM for native GLP-1 and 5 pM for native glucagon, respectively. In practical terms, survodutide is roughly four-fold less potent than endogenous GLP-1 at its own receptor and roughly twenty-two-fold less potent than endogenous glucagon at the glucagon receptor — a deliberately balanced, submaximal dual agonism rather than a maximal one.
That balance matters clinically. Unopposed glucagon receptor agonism raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis; pairing it with GLP-1 receptor agonism, which stimulates glucose-dependent insulin secretion and suppresses glucagon-driven hyperglycemia, is intended to offset that risk while preserving the lipolytic and thermogenic signal from GCGR activation.
Downstream, glucagon receptor engagement in hepatocytes activates cAMP/PKA signaling that upregulates fatty-acid oxidation genes and suppresses de novo lipogenesis, a mechanism distinct from the reduced caloric intake that drives most GLP-1 monotherapy weight loss. This is the pharmacological basis for testing survodutide specifically in metabolic dysfunction-associated steatohepatitis (MASH), where hepatic fat content, not body weight alone, is the primary lesion under study.
Phase 2 Obesity Trial: Design and Dosing (NCT04667377)
The dose-finding obesity trial (Le Roux et al., Lancet Diabetes Endocrinol 2024;12:162-73, PMID 38330987; ClinicalTrials.gov NCT04667377) enrolled 386 adults ages 18-74 with BMI ≥27 kg/m² and no diabetes across 43 centers in 12 countries. It was a randomized, double-blind, placebo-controlled, parallel-group study — the standard evidence tier for dose-ranging work before a phase 3 program is committed.
Participants were assigned to once-weekly subcutaneous survodutide targeting final doses of 0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg, or to placebo. Dosing followed a 20-week escalation phase intended to blunt gastrointestinal tolerability issues, followed by a 26-week maintenance phase, for 46 weeks of total exposure. This escalation structure mirrors the titration logic covered in detail in semaglutide dose titration protocols from pivotal trials, where slow escalation is used across the drug class to manage nausea and vomiting rather than to change the ultimate efficacy ceiling.
The primary endpoint was percent change in body weight from baseline to week 46, analyzed both by intention-to-treat using planned dose and by an on-treatment (trial-product) estimand restricted to participants who tolerated and maintained their assigned dose — a distinction that matters for interpreting the headline numbers below.
Weight-Loss Outcomes at Week 46
In the intention-to-treat analysis, mean placebo-corrected weight change at week 46 was dose-dependent: -6.2% at 0.6 mg, -12.5% at 2.4 mg, -13.2% at 3.6 mg, and -14.9% at 4.8 mg, compared with -2.8% for placebo (PMID 38330987). Among participants in the 4.8 mg arm who actually maintained the full assigned dose across the maintenance phase — the on-treatment estimand — mean weight loss reached 18.7%, versus 2.3% for placebo.
Secondary responder analyses in the 4.8 mg group found that 83% of participants lost at least 5% of body weight, 69% lost at least 10%, and 55% lost at least 15% by week 46. Close to 40% of participants receiving the highest dose lost 20% or more of their starting weight — a magnitude that places survodutide in the same range reported for high-dose tirzepatide (Mounjaro/Zepbound) in comparative weight-loss trial data, though no head-to-head trial between survodutide and either approved agent has been published.
The gap between the intention-to-treat figure (14.9%) and the on-treatment figure (18.7%) is not a discrepancy — it reflects the difference between "everyone randomized to this dose" and "everyone who could actually stay on this dose," and it is a gap that shows up across the GLP-1 class whenever gastrointestinal tolerability limits dose maintenance. Reporting only the larger number without the smaller one is a common promotional distortion; both numbers come from the same trial and the same peer-reviewed source.
Tolerability and Adverse Events in the Obesity Trial
Adverse events of any kind occurred in 91% of survodutide recipients (281 of 309) versus 75% of placebo recipients (58 of 77). Gastrointestinal disorders — nausea, vomiting, diarrhea, and decreased appetite — were the most frequently reported category, occurring in 75% of survodutide recipients versus 42% of placebo recipients, consistent with the class-wide delayed-gastric-emptying mechanism documented for GLP-1 receptor agonists generally.
Because glucagon receptor agonism carries a theoretical glucose-elevating effect, glycemic parameters were tracked closely throughout the trial; no clinically meaningful increase in fasting glucose was reported at the doses tested in this non-diabetic population, though this is a monitoring point that carries more weight in populations with impaired glucose tolerance.
Discontinuation due to adverse events was more common in survodutide arms than placebo, tracking with the dose-escalation-related GI burden seen across dual and triple agonists. For a compound still in phase 2, this tolerability signal is directionally reassuring — it resembles existing GLP-1 receptor agonist safety profiles rather than introducing a novel adverse-event category — but it is not yet characterized in the larger, longer-duration populations that a phase 3 program requires before firm safety conclusions are appropriate.
Phase 2 MASH Trial: Design and Population (NCT04771273)
The liver-focused phase 2 trial (Sanyal et al., N Engl J Med 2024;391:299-310, PMID 38847460; ClinicalTrials.gov NCT04771273) enrolled 293 adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 — a population selected specifically because biopsy confirmation, not imaging alone, is still the reference standard for histologic endpoints in liver trials.
Participants were randomized 1:1:1:1 to once-weekly subcutaneous survodutide at 2.4 mg, 4.8 mg, or 6.0 mg, or to placebo. As in the obesity trial, dosing followed a 24-week rapid-escalation phase followed by a 24-week maintenance phase, for 48 weeks of total treatment exposure before the end-of-study liver biopsy.
The primary endpoint was histologic improvement in MASH (a reduction in the NAFLD activity score components) with no worsening of fibrosis stage, assessed by paired liver biopsy at baseline and week 48 and read by blinded central pathologists. Key secondary endpoints included fibrosis improvement of at least one stage without worsening of steatohepatitis, and relative reduction in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF).
Liver Fat and Histology Results at 48 Weeks
Improvement in MASH with no worsening of fibrosis — the trial's primary endpoint — occurred in 47% of participants on the 2.4 mg dose, 62% on 4.8 mg, and 43% on 6.0 mg, compared with 14% on placebo (PMID 38847460). All three active doses reached statistical significance against placebo.
On MRI-PDFF, a relative reduction in liver fat content of at least 30% occurred in 63% (2.4 mg), 67% (4.8 mg), and 57% (6.0 mg) of participants, compared with 14% on placebo. Fibrosis improvement of at least one stage without worsening of steatohepatitis occurred in 34%, 36%, and 34% of the 2.4 mg, 4.8 mg, and 6.0 mg groups respectively, versus 22% on placebo — a smaller effect size than the steatohepatitis endpoint, and one where the confidence intervals versus placebo are correspondingly tighter.
Two details are worth flagging for anyone reading only the topline percentages. First, the 4.8 mg dose outperformed the 6.0 mg dose on the primary endpoint (62% versus 43%), a non-monotonic pattern the authors attribute at least in part to tolerability-driven dose reductions and dropout at the highest dose rather than a true pharmacological ceiling. Second, this is a single phase 2 trial with a 48-week endpoint — durability beyond one year and reproducibility in a larger phase 3 population are not yet established.
How the Liver Signal Compares Across Dual and Triple Agonists
Survodutide's MASH data joins a small but growing set of incretin-based liver trials. Tirzepatide's SYNERGY-NASH trial, covered in liver outcomes on tirzepatide from the SYNERGY-NASH 52-week results, reported histologic improvement without worsening of fibrosis at rates that are broadly comparable in direction, though the two trials differ in dosing schedule, endpoint timing (48 vs. 52 weeks), and population, so a formal head-to-head comparison is not possible from published data alone.
Retatrutide, a GIP/GLP-1/glucagon triple agonist, has shown large reductions in liver fat as a secondary outcome in its own phase 2 obesity program, but that trial did not use biopsy-confirmed MASH as an enrollment criterion or a primary histologic endpoint, making survodutide's data — collected in a biopsy-defined population — a more direct test of the liver-specific hypothesis.
The mechanistic argument for glucagon receptor agonism producing liver benefit independent of weight loss is plausible given the hepatocyte-level fatty-acid oxidation pathway described earlier, but the phase 2 trial design does not isolate that variable from weight loss itself — both occurred concurrently in the same participants. Whether the glucagon component adds a liver-specific effect beyond what equivalent weight loss from GLP-1 monotherapy would produce remains an open question that only a mechanistic sub-study or an appropriately matched comparator arm could answer.
Regulatory Status and the Phase 3 Programs Underway
In October 2024, survodutide received FDA Breakthrough Therapy Designation for non-cirrhotic MASH with moderate-to-advanced fibrosis, a status that expedites FDA review and interaction but is not an approval and does not permit marketing for that indication. Survodutide is not currently FDA-approved for any use, and its research-only status carries the same supplier-landscape caveats — inconsistent sterility documentation, variable third-party purity testing — described in compounded semaglutide versus FDA-approved brands on stability and sterility, which applies with even more force to an investigational molecule with no approved formulation at all.
Boehringer Ingelheim has advanced survodutide into phase 3 with the LIVERAGE and LIVERAGE-Cirrhosis programs for MASH and MASH-related cirrhosis, and the SYNCHRONIZE program for obesity and overweight, including trials that pair survodutide with cardiovascular and renal outcome tracking similar in structure to the renal endpoints now being reported across the GLP-1 receptor agonist class.
Until those phase 3 trials read out, survodutide's evidence tier remains phase 2: dose-ranging, hypothesis-generating, and statistically significant against placebo in two separate populations, but not yet replicated at the scale or duration regulators require for an approval decision.
What This Means for Monitoring and Ongoing Research
For clinicians and researchers tracking this compound, several open questions determine how much weight the phase 2 data should carry today. Durability past 48-52 weeks is unconfirmed; whether fibrosis regression is maintained, lost, or extended with continued dosing is a phase 3 question, not a phase 2 answer. Cardiovascular outcome data comparable to the four-year follow-up summarized in the GLP-1 cardiovascular outcomes SELECT trial four-year follow-up review does not yet exist for survodutide and would be necessary before any comparative claims about cardiovascular benefit are appropriate.
Biopsy-based histologic endpoints, while the reference standard, carry known sampling variability — two biopsies from the same liver at the same time point can disagree on fibrosis stage in a meaningful minority of cases, which is one reason regulators generally require replication across independent phase 3 cohorts before accepting a histologic claim.
Practical monitoring for anyone following this compound's progress: track the LIVERAGE and SYNCHRONIZE program completion dates listed on ClinicalTrials.gov, watch for peer-reviewed phase 3 publication rather than press-release topline figures, and treat the 62% MASH-improvement figure at 4.8 mg as a phase 2 dose-finding result, not a settled clinical outcome, until an independent, larger trial reproduces it.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.